Prospective study comparing quality of life between opioids sparing protocol and WHO guideline in metastatic bone cancer

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20180503005

Enrollment

240

Registered

2018-05-03

Start date

2018-01-23

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain Opioid consumptiom Survaval rate

Interventions

Opioid drug follow WHO guildline,Opioid sparing protocol &#45

acetaminophen 1500&#45

4000 mg/day &#45

Naproxen or celebrex &#45

Gabapentonoid &#45

Dexamethasone&#44

bisphodphonate or denosumab

Experimental Drug,Experimental Drug

WHO guildline,Opioid sparing protocol

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age more than 18 2. Radiographic evidence of bone metastasis with corresponding pain at that site 3. Life expectancy 3 month or more and Kanofsky performance status > 40 4. Moderate to severe bone pain ( pain scose more than 3 out of 10 )

Exclusion criteria

Exclusion criteria: Patients rufuse

Design outcomes

Primary

Measure	Time frame
To compare quality of life 1 year Edmonton symptom assessment scale, ESAS, BPI	—

Secondary

Measure	Time frame
Pain score 1 year NRS,Opioid consumption 1 year Morphine equivalent,Opioid related side effect 1 year BPI,Kanofsky score 1 year Kanofsky score	—

Contacts

Public ContactNantthasorn Zinboonyahgoon

Faculty of medicine Mahidol university

Nantthasorn@gmail.com0947761286

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026